NEO · NeoGenomics Laboratories, Inc. Q2 FY2026 earnings call record财报电话会记录

“Please refer to the information disclosed on the safe harbor statement slide in the deck posted on our website, as well as the information under the heading Risk Factors in our most recent Forms 10-K, 10-Q, and 8-K that were filed with the SEC to identify important risks or other factors that may cause our actual results to differ materially from the forward-looking statements.”

“Our top-line performance continues to be driven by our clinical business, which grew by 14% in the quarter as AUP increased 12% and volume exceeded our target and grew 2%.”

“Clinical volumes increased 2%, exceeding our expectations, while NGS volume was broad-based across both heme and solid tumor testing, growing 14%.”

“This quarter, we closed two dry labs, optimized administrative footprints, further balanced volumes across our laboratory network, exited low-margin non-oncology business acquired with Pathline, and captured additional AI-driven automation efficiencies.”

“We also completed the transition of PanTracer LBx as our first clinical assay to the NovaSeq X platform, an important milestone that we believe allows us to process liquid biopsy volumes with greater throughput, improved TAT, and lower per-test cost at volume scale, supporting both our gross margin expansion goals and our ability to serve more patients.”

“Clinical revenue grew a strong 14% year-over-year, driven by a 2% increase in test volumes and a 12% increase in AUP.”

“We are pleased to see the mix shift towards high-value testing continue to build, with NGS revenue growth of 26%, driven by volume growth of 14%.”

“Considering our strong second quarter revenue performance, we are raising our full year 2026 revenue guidance to a range of $802 million-$806 million, up from $797 million-$803 million discussed previously.”

“We're also raising our full year 2026 adjusted EBITDA guidance to a range of $56 million-$58 million versus $55 million-$57 million previously, representing year-over-year growth of over 30% at the midpoint.”

“If you break down that Q2, if you look at that 26%, it's like 14% was volume and 12% was AUP, which about two-thirds of that was mixed.”

“What we had basically said previously that this high volume, low value contract made up about 3%-4% of our volumes in 2025.”

“Of course, we'll start to see the impact on our credentials as we basically ramp up the volumes, but that's the kind of effort that the team has been doing on the managed care side to drive the policy and the coverage.”